John T Bates

List of Publications by Year in descending order

26 papers	1,497 citations	471509 17 h-index	610901 24 g-index
27 all docs	27 docs citations	27 times ranked	2842 citing authors

#	Article	IF	Citations
1	Efficacy of POC Antibody Assays after COVID-19 Infection and Potential Utility for â€œImmunity Passportsâ€• Laboratory Medicine, 2022, 53, 262-265.	1.2	0
2	Potential Anti-SARS-CoV-2 Activity of Pentosan Polysulfate and Mucopolysaccharide Polysulfate. Pharmaceuticals, 2022, 15, 258.	3.8	20
3	Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots. ACS Omega, 2022, 7, 8150-8157.	3.5	10
4	IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity. Vaccines, 2022, 10, 512.	4.4	11
5	Heparan sulfates from bat and human lung and their binding to the spike protein of SARS-CoV-2 virus. Carbohydrate Polymers, 2021, 260, 117797.	10.2	21
6	The degree of polymerization and sulfation patterns in heparan sulfate are critical determinants of cytomegalovirus entry into host cells. PLoS Pathogens, 2021, 17, e1009803.	4.7	17
7	Tegument Protein pp150 Sequence-Specific Peptide Blocks Cytomegalovirus Infection. Viruses, 2021, 13, 2277.	3.3	2
8	Anti-SARS-CoV-2 Activity of Rhamnan Sulfate from Monostroma nitidum. Marine Drugs, 2021, 19, 685.	4.6	30
9	Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein. Scientific Reports, 2020, 10, 19076.	3.3	24
10	De novo protein design enables the precise induction of RSV-neutralizing antibodies. Science, 2020, 368, .	12.6	137
11	Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nature Microbiology, 2017, 2, 16272.	13.3	65
12	Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6849-E6858.	7.1	38
13	Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates. Vaccine, 2016, 34, 950-956.	3.8	26
14	Pigs immunized with Chinese highly pathogenic PRRS virus modified live vaccine are protected from challenge with North American PRRSV strain NADC-20. Vaccine, 2015, 33, 3518-3525.	3.8	17
15	STAT4 Deficiency Fails To Induce Lung Th2 or Th17 Immunity following Primary or Secondary Respiratory Syncytial Virus (RSV) Challenge but Enhances the Lung RSV-Specific CD8 ⁺ T Cell Immune Response to Secondary Challenge. Journal of Virology, 2014, 88, 9655-9672.	3.4	8
16	Proof of principle for epitope-focused vaccine design. Nature, 2014, 507, 201-206.	27.8	451
17	Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein. Virology, 2014, 454-455, 139-144.	2.4	31
18	Reversion of Somatic Mutations of the Respiratory Syncytial Virusâ€“Specific Human Monoclonal Antibody Fab19 Reveal a Direct Relationship between Association Rate and Neutralizing Potency. Journal of Immunology, 2013, 190, 3732-3739.	0.8	26

#	Article	IF	Citations
19	Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs, 2013, 5, 263-269.	5.2	28
20	Enhanced Antigen Processing of Flagellin Fusion Proteins Promotes the Antigen-Specific CD8+T Cell Response Independently of TLR5 and MyD88. Journal of Immunology, 2011, 186, 6255-6262.	0.8	34
21	Response to Comment on â€œFlagellin as an Adjuvant: Cellular Mechanisms and Potentialâ€. Journal of Immunology, 2011, 186, 1299.2-1299.	0.8	0
22	Flagellin as an Adjuvant: Cellular Mechanisms and Potential. Journal of Immunology, 2010, 185, 5677-5682.	0.8	330
23	Direct Stimulation of tlr5+/+ CD11c+ Cells Is Necessary for the Adjuvant Activity of Flagellin. Journal of Immunology, 2009, 182, 7539-7547.	0.8	76
24	Mucosal adjuvant activity of flagellin in aged mice. Mechanisms of Ageing and Development, 2008, 129, 271-281.	4.6	52
25	Expression of a nonâ€“DNA-binding isoform of Helios induces T-cell lymphoma in mice. Blood, 2007, 109, 2190-2197.	1.4	32
26	Enhanced responsiveness to antigen contributes more to immunological memory in CD4 T cells than increases in the number of cells. Immunology, 2005, 116, 318-327.	4.4	5